Yes, gabapentin has been the subject of major lawsuits, most notably a $430 million federal settlement over illegal marketing and a $325 million class action settlement on behalf of insurance companies that paid for the drug. While those landmark cases have resolved, gabapentin continues to surface in individual malpractice claims related to overdose deaths and breathing problems.
The $430 Million Federal Settlement
The largest legal action against gabapentin’s manufacturer came in 2004, when Warner-Lambert (the company behind the Parke-Davis division that made Neurontin) agreed to plead guilty and pay more than $430 million to resolve both criminal charges and civil liabilities. The case centered on illegal promotion of gabapentin for conditions it was never approved to treat.
Gabapentin received FDA approval in 1993 solely as an add-on treatment for seizures in people with epilepsy. It has since also been approved for postherpetic neuralgia, the nerve pain that lingers after shingles. Those remain its only two FDA-approved uses today. But Warner-Lambert’s sales team aggressively marketed the drug for bipolar disorder, migraines, attention deficit disorder, restless leg syndrome, various pain conditions, ALS, and alcohol and drug withdrawal seizures. None of these uses had FDA approval.
The settlement broke down into several components. Warner-Lambert paid a $240 million criminal fine, which at the time was the second-largest criminal fine ever imposed in a healthcare fraud case. Another $83.6 million went to the federal government for losses to the Medicaid program. The fifty states and Washington, D.C., received $68.4 million for their Medicaid losses, plus an additional $38 million to address harm caused to consumers. Pfizer inherited the case after acquiring Warner-Lambert.
The $325 Million Insurance Class Action
A separate wave of litigation came from insurance companies and other organizations that had paid for gabapentin prescriptions written for unapproved uses. The most prominent plaintiff was Kaiser Foundation Health Plan, which argued it had been misled into covering gabapentin for neuropathic pain, migraines, and bipolar disorder based on Pfizer’s fraudulent marketing.
In March 2010, a federal jury found that Pfizer violated a federal anti-racketeering law by promoting gabapentin for unapproved uses without evidence that it actually worked for those conditions. The jury determined Pfizer owed Kaiser up to $142 million in damages. That verdict helped build momentum for a broader class action representing insurance companies and other third-party payers nationwide. In November 2014, the court approved a $325 million settlement for that class.
Gabapentin and Overdose Deaths
More recent legal concerns involve gabapentin’s role in overdose deaths, particularly when combined with opioids. A report published in the Journal of the American Medical Association found that postmortem toxicology tests detected gabapentin in nearly 10% of all overdose deaths in the United States during 2019 and 2020. In half of those cases, gabapentin was identified as a contributing cause of death.
In December 2019, the FDA issued a safety warning that gabapentin can cause serious breathing difficulties in certain patients. Those at highest risk include people taking opioid painkillers or other drugs that suppress the central nervous system, people with chronic lung conditions like COPD, and elderly patients. This warning has given legal weight to individual malpractice claims arguing that doctors failed to check for dangerous drug interactions before prescribing gabapentin alongside opioids.
These cases are typically filed as individual medical malpractice lawsuits rather than class actions. They generally allege that a healthcare provider was negligent in prescribing gabapentin without reviewing the patient’s other medications or assessing their respiratory risk factors.
What About Current Class Actions?
The major class action lawsuits over gabapentin’s off-label marketing have been resolved. As of now, there is no large, active class action seeking new plaintiffs for gabapentin-related injuries. Some legal websites advertise potential cases involving side effects like dental damage or memory loss, but there is currently no established class action focused on those specific harms.
That said, individual lawsuits remain possible. If a patient suffered a serious injury that can be linked to gabapentin, particularly involving respiratory depression, overdose, or a prescriber’s failure to account for known risks, that could form the basis of a malpractice claim. The strength of any individual case depends on the medical records, the specific circumstances of the prescription, and whether the prescribing provider followed the safety steps the FDA has outlined.
Why Off-Label Prescribing Still Matters
One detail that surprises many people is how commonly gabapentin is still prescribed for conditions it was never approved to treat. Doctors are legally allowed to prescribe any FDA-approved drug for off-label uses based on their clinical judgment. What Warner-Lambert did wrong was not that patients received gabapentin off-label, but that the company systematically promoted those uses through its sales force while knowing it lacked evidence the drug worked for them.
If you’re currently taking gabapentin for something other than epilepsy-related seizures or post-shingles nerve pain, that is an off-label use. This is common across medicine and not inherently dangerous. But given gabapentin’s legal history, it is worth understanding that much of the evidence your prescriber relied on may be more limited than for the drug’s approved uses.